Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Lamb Weston Holdings Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Lamb Weston Holdings Inc trades at $53.22 (market cap $7.16B). The key difference: Lamb Weston Holdings Inc is far larger — about 2.5× Dyne Therapeutics Inc. Common Stock's market cap, and Lamb Weston Holdings Inc pays a 2.93% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Lamb Weston Holdings Inc for 66 Days on average.
| DYN | LW | |
|---|---|---|
Market Cap | $2.86B | $7.16B |
Volume | 3,341,579 | 2,766,229 |
Sector | Health | Consumer Staples |
52-Week High | $26.78 | $66.57 |
52-Week Low | $14.60 | $38.48 |
Typical Hold Time | 0 Days | 66 Days |
Enterprise Value | $2.18B | $10.95B |
Dividend Yield | — | 2.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Lamb Weston (LW) trades at $53.02, up 5.66% today, near the consensus price target of $53.71. The stock shows bullish technical signals with strong moving averages and recent earnings beats. Revenue reached $6.45B in 2025, though net income margin compressed to 3.85%. The company maintains a solid balance sheet with $70.70M cash and ongoing dividend payments of $0.38 per share.
Outlook remains mixed; analyst consensus leans Hold (63%) with potential upside to $58.00. Key risks include margin pressure from high debt and volatile earnings. Positive sentiment from cost-saving initiatives supports recovery, but investor confidence hinges on sustained profitability improvements amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
